Dinutuximab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin for the treatment of high-risk neuroblastoma; it effectively prolongs event-free survival and overall survival.